Current and future directions of pharmacokinetic and pharmacokinetic–pharmacodynamic modelling and simulation: Population Approach Group in Europe 19th annual meeting

Bibliography

• Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's ‘Guidance for industry: population pharmacokinetics’. Clin Pharmacokinet 2000;39:385-95
   PubMed Web of Science ®Google Scholar
• Available from: http://www.page-meeting.org [Accessed 30 Septemeber 2010]
   Google Scholar
• Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007;3:235-49
   PubMed Web of Science ®Google Scholar
• Kapitulnik J, Pelkonen O, Gundert-Remy U, Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models. Expert Opin Ther Targets 2009;13:867-87
   PubMed Web of Science ®Google Scholar
• Lave' T, Parrott N, Grimm HP, Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007;37:1295-310
   PubMed Web of Science ®Google Scholar
• Huisinga W. Physiologically-based pharmacokinetic/pharmacodynamic modelling, mathematical model reduction and a mechanistic interpretation of simple empirical models [abstract 1940]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1940
   Google Scholar
• Pilari S, Huisinga W. Lumping of physiologically based pharmacokinetic models and a mechanistic derivation of classical compartmental models [abstract 1929]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1929
   Google Scholar
• Pilari S, Huisinga W. Lumping of physiologically based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn 2010;37:365-405
   PubMed Web of Science ®Google Scholar
• Eissing T, Lippert J, Willmann S. Investigation of the influence of CYP3A4 inhibition and renal impairment on morphine and M6G formation after codein administration using coupoled whole-body PBPK modelling [abstract 1861]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1861
   Google Scholar
• Bazzoli C, Retout S, Mentre F. Design evaluation and optimisation in multi-response nonlinear mixed effect models with cost functions: application to the pharmacokinetics of zidovudine and its active metabolite [abstract 1710]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1710
   Google Scholar
• Dua P, Pons N, Bertolotti L, SB-773812: correlation between in-silico and in-vivo metabolism [abstract 1723]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1723
   Google Scholar
• Kallenbach M, Hovener J, Kersting G, Evaluation of a physiologically-based pharmacokinetic (PBPK) model for the application of low dose etoposide in children [abstract 1881]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1881
   Google Scholar
• Gerard C, Bleyzac N, Girard P, Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model [abstract 1924]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1924
   Google Scholar
• Krzyzanski W. An interpretation of transit compartment pharmacodynamic models as lifespan-based indirect response models [abstract 1766]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1766
   Google Scholar
• Friberg LE, Henningsson A, Maas H, Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E. Target-mediated drug disposition: new derivation of the Michaelis–Menten model, and why it is often sufficient for description of drugs with TMDD [abstract 1728]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1728
   Google Scholar
• Keizer RJ, Funahashi Y, Semba T, Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker [abstract 1690]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1690
   Google Scholar
• Ribba B, Watkin E, Tod M, Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice [abstract 1801]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1801
   Google Scholar
• Johnson M, Kozielska M, Pilla Reddy V, Evaluation of a mechanism-based pharmacokinetic-pharmacodynamic model for D2 receptor occupancy of olanzapine in rats [abstract 1808]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1808
   Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic-pharmacodynamic modelling for antibiotics: static and dynamic in vitro time-kill curve experiments [abstract 1806]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1806
   Google Scholar
• Dubois VFS, Shearer M, Chain A, Translation of drug-induced QTc prolongation in early drug development [abstract 1812]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1812
   Google Scholar
• Zamuner S, Paronetto M, Moscardo E, The assessment of convulsion risk: a translational PK/PD modelling approach [abstract 1867]; 2010. 19. Available from: www.page-meeting.org/?abstract=1867
   Google Scholar
• Delattre M, Savic R, Miller R, Estimation of mixed hidden Markov models with SAEM. Application to daily seizures data [abstract 1694]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1694
   Google Scholar
• Plan EL, Karlsson KE, Karlsson MO. Analysis approaches handling both symptomatic severity and frequency [abstract 1711]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1711
   Google Scholar
• Plan EL, Karlsson KE, Karlsson MO. Approaches to simultaneous analysis of frequency and severity of symptoms. Clin Pharmacol Ther 2010;88(2):255-9
   PubMed Web of Science ®Google Scholar
• Lim LA, Miller R, Park K. Dose-response-dropout analysis for pregabalin-treated patients with generalized anxiety disorders [abstract 1703]; 2010. p. 19. Available from: www.page-meeting.org/?abstract=1703
   Google Scholar
• Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf [Accessed 28 July 2010]
   Google Scholar